Nature Search

Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade

Renato A. Guerrieri
Grant M. Fischer
Sherise D. Ferguson
ResearchOpen Access02 Oct 2025
Scientific Reports

Volume: 15, P: 1-15
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

In an interim analysis of a phase 1 trial of concurrent intrathecal and intravenous anti-PD1 delivery in patients with leptomeningeal disease and melanoma, treatment was feasible and well-tolerated with no dose-limiting toxicities.

Isabella C. Glitza Oliva
Sherise D. Ferguson
Michael A. Davies
ResearchOpen Access30 Mar 2023
Nature Medicine

Volume: 29, P: 898-905
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Isabella C. Glitza Oliva
Sherise D. Ferguson
Michael A. Davies
Amendments and CorrectionsOpen Access22 Apr 2024
Nature Medicine

Volume: 30, P: 1787
Neoadjuvant relatlimab and nivolumab in resectable melanoma

Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.

Rodabe N. Amaria
Michael Postow
Hussein A. Tawbi
ResearchOpen Access26 Oct 2022
Nature

Volume: 611, P: 155-160
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Sang T. Kim
Yanshuo Chu
Roza Nurieva
Amendments and CorrectionsOpen Access04 Jul 2024
Nature Communications

Volume: 15, P: 1
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Arthritis is the most common rheumatic immune-related adverse event (irAE) occurring in cancer patients receiving immune checkpoint inhibitors. Here the authors study the immune landscape of blood and synovial fluid samples from patients with arthritis-irAE, reporting immunological differences and similarities with classic autoimmune arthritis.

Sang T. Kim
Yanshuo Chu
Roza Nurieva
ResearchOpen Access12 Apr 2022
Nature Communications

Volume: 13, P: 1-19
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Clinical benefit or intestinal toxicity resulting from combined immune checkpoint blockade in patients with melanoma associates with prevalent commensal bacteria and can be decoupled by IL-1R inhibition.

Miles C. Andrews
Connie P. M. Duong
Jennifer A. Wargo
Research08 Jul 2021
Nature Medicine

Volume: 27, P: 1432-1441
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Rodabe N. Amaria
Michael Postow
Hussein A. Tawbi
Amendments and CorrectionsOpen Access09 Mar 2023
Nature

Volume: 615, P: E23
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria
Sangeetha M. Reddy
Jennifer A. Wargo
Amendments and Corrections25 Oct 2018
Nature Medicine

Volume: 24, P: 1941
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria
Sangeetha M. Reddy
Jennifer A. Wargo
Amendments and Corrections25 Oct 2018
Nature Medicine

Volume: 24, P: 1942
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.

Rodabe N. Amaria
Sangeetha M. Reddy
Jennifer A. Wargo
Research08 Oct 2018
Nature Medicine

Volume: 24, P: 1649-1654
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

Alexandre Reuben
Christine N. Spencer
Jennifer A. Wargo
ResearchOpen Access07 Apr 2017
npj Genomic Medicine

Volume: 2, P: 1-11

Search

Filter By:

Search

Quick links